Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007934 | 1.00 | KDM4E (0.86) | KDM4EPKMALDH1A1MAPK1VCAM1 | |
| SCHEMBL23148212 | 0.87 | KDM4E (0.67) | KDM4EPKMALDH1A1MAPK1VCAM1 | |
| SCHEMBL30008583 | 0.87 | KDM4E (0.67) | KDM4EPKMALDH1A1MAPK1VCAM1 | |
| SCHEMBL28508912 | 0.84 | KDM4E (0.62) | KDM4EPKMALDH1A1MAPK1VCAM1 | |
| SCHEMBL6564231 | 0.83 | KDM4E (0.61) | KDM4EPKMALDH1A1MAPK1LMNA | |
| SCHEMBL6563554 | 0.81 | KDM4E (0.59) | KDM4EPKMALDH1A1MAPK1LMNA | |
| SCHEMBL1873507 | 0.81 | PKM (1.00) | KDM4EPKMALDH1A1MAPK1LMNA | |
| SCHEMBL5813426 | 0.81 | ALDH1A1 (0.87) | KDM4EPKMALDH1A1MAPK1LMNA | |
| SCHEMBL3435820 | 0.80 | ALDH1A1 (0.65) | KDM4EPKMALDH1A1MAPK1KMT2A | |
| SCHEMBL27548843 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1MAPK1VCAM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749645-B1 | 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE | VIB VZW (BE) | 2025-01-22 | — | — | EP | disclosed |
| CN-112105601-B | Benzenesulfonamide derivatives and related FERROSTATIN-1 analogs as cell death inhibitors | 维伯VZW公司 | 2022-11-18 | — | — | CN | disclosed |
| US-11339124-B2 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | UNIVERSITEIT ANTWERPEN (BE) | 2022-05-24 | — | — | US | disclosed |
| US-20210094909-A1 | 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE | VIB VZW (BE) | 2021-04-01 | — | — | US | disclosed |
| CN-112105601-A | 3- (benzylamino) -4- (cyclohexylamino) -N- (2-piperazin-1-yl) ethyl) benzenesulfonamide derivatives and related FERROSTATIN-1 analogs as cell death inhibitors for the treatment of, for example, stroke | 维伯VZW公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3749645-A1 | 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE | VIB vzw (BE) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154795-A1 | 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE | VIB VZW (BE) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339124-B2 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | AIFM2, AIFM1, FECH | KDM4E 1954/4885PKM 1509/4885ALDH1A1 1533/4885 |
| US-20210094909-A1 | 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE | AIFM2, AIFM1, FECH | KDM4E 1954/4885PKM 1509/4885ALDH1A1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.